Methods and compositions for treating eukaryotic infections via altering aggregation dynamics of raptor/kog1
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsAndrew P. Capaldi, James E. Hughes Hallett
Life of this patent
Estimating the term…
Abstract
Methods and compositions for activating TORC1 aggregate formation in a fungi or a parasite, wherein TORC1 aggregate formation inhibits growth of the fungi or parasite. TORC1 aggregate formation may be activated using small molecules or other agents, and said agents may be used to treat or prevent a disease or condition associated with the fungi and parasite. The agent may target Kog1 of TORC1, e.g., the agent may directly or indirectly inhibit Kog1 leading to aggregation of the TORC1 complex.
Claims21
A method of treating or preventing a disease or a condition associated with a fungi or a parasite in a subject in need thereof, said method comprising administering an agent that activates TORC1 aggregate formation to the subject that has been identified as having a disease or condition associated with a fungi or parasite, the TORC1 aggregate formation inhibits growth of the fungi or parasite.
A method of inhibiting fungal or parasitic survival or replication in vitro, said method comprising applying to a cell or an in vitro system an agent that activates TORC1 aggregate formation, the TORC1 aggregate formation inhibits growth of the fungi or parasite.
A method of inhibiting fungal or parasitic survival or replication in an animal or a plant in need thereof, said method comprising administering to the animal or applying to the plant an agent that activates TORC1 aggregate formation, the TORC1 aggregate formation inhibits growth of the fungi or parasite.
15-19. (canceled)
The method of claim 16, wherein the small molecule comprises metformin, PT 1, salicylsalicylic acid, Phenformin, AICAR, A-769662, Acadesine, orsomorphin, 1,1-Dimethylbiguanide hydrochloride, or BML-275.
The method of claim 19, wherein the small molecule comprises metformin, PT 1, salicylsalicylic acid, Phenformin, AICAR, A-769662, Acadesine, orsomorphin, 1,1-Dimethylbiguanide hydrochloride, or BML-275.
Dependencies are inferred from the claim text.